PMID- 35965499
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220816
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - A novel HCC prognosis predictor PDSS1 affects the cell cycle through the STAT3 
      signaling pathway in HCC.
PG  - 927468
LID - 10.3389/fonc.2022.927468 [doi]
LID - 927468
AB  - Decaprenyl diphosphate synthase subunit 1 (PDSS1) is closely related to a variety 
      of human diseases, but its expression pattern and biological function in HCC have 
      not been studied to date. METHODS: The expression level of PDSS1 was analyzed 
      using the TCGA and GEO databases. The relationships between PDSS1 and patient 
      clinicopathological characteristics were verified based on TCGA clinical data. 
      Additionally, the co-expressed genes of PDSS1were investigated and Gene Set 
      Enrichment Analysis (GSEA) was conducted using LinkedOmics. Next, the association 
      between PDSS1 and immune infiltration was determined using version 1.34.0 of the 
      GSVA package. EdU assay, colony-formation assay, transwell assay, wound-healing 
      assay, and flow cytometry analysis were used to assess the effect of PDSS1 on the 
      cell phenotype. RESULTS: PDSS1 was upregulated in HCC compared with adjacent 
      tissues. High PDSS1 in HCC was associated with poor overall survival, 
      disease-specific survival, and progress-free interval. Results suggested that 
      PDSS1 may activate multiple oncogenic pathways in HCC, especially those involved 
      in the cell cycle. The expression of PDSS1 was significantly related to Th2 
      cells, TFH, T helper cells, NK CD56bright cells, cytotoxic cells, DC, CD8 T 
      cells, and neutrophils. PDSS1 knockdown inhibited cell proliferation, cell cycle, 
      migration and invasion. Furthermore, PDSS1 acted as an oncogene through the STAT3 
      signaling pathway. CONCLUSION: Our study reveals that a high level of PDSS1 is 
      significantly correlated with poor patient prognosis and immune cell infiltration 
      in HCC. PDSS1 may be a novel biomarker and potential therapeutic target for HCC.
CI  - Copyright (c) 2022 Rao, Li, Yao, Wang, Ma, Xue and Meng.
FAU - Rao, Zuqin
AU  - Rao Z
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
AD  - Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First 
      Affiliated Hospital of Harbin Medical University, Harbin, China.
FAU - Li, Heng
AU  - Li H
AD  - Department of Comprehensive Surgery, The First Affiliated Hospital of University 
      of Science and Technology of China (USTC) West District/Anhui Provincial Cancer 
      Hospital, Hefei, China.
FAU - Yao, Wenchao
AU  - Yao W
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
AD  - Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First 
      Affiliated Hospital of Harbin Medical University, Harbin, China.
FAU - Wang, Qiang
AU  - Wang Q
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
AD  - Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First 
      Affiliated Hospital of Harbin Medical University, Harbin, China.
FAU - Ma, Biao
AU  - Ma B
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
AD  - Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First 
      Affiliated Hospital of Harbin Medical University, Harbin, China.
FAU - Xue, Dongbo
AU  - Xue D
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
AD  - Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First 
      Affiliated Hospital of Harbin Medical University, Harbin, China.
FAU - Meng, Xianzhi
AU  - Meng X
AD  - Department of General Surgery, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
AD  - Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First 
      Affiliated Hospital of Harbin Medical University, Harbin, China.
LA  - eng
PT  - Journal Article
DEP - 20220728
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9368321
OTO - NOTNLM
OT  - PDSS1
OT  - STAT3
OT  - cell cycle
OT  - immune infiltration
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/16 06:01
PMCR- 2022/01/01
CRDT- 2022/08/15 03:25
PHST- 2022/04/24 00:00 [received]
PHST- 2022/07/04 00:00 [accepted]
PHST- 2022/08/15 03:25 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/16 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.927468 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jul 28;12:927468. doi: 10.3389/fonc.2022.927468. eCollection 
      2022.